Navigation Links
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Date:9/24/2007

ent with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

Additional Safety Information

Relapse of drug addiction/overdose has occurred in patients on PEGINTRON therapy. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully followed with psychiatric intervention, as appropriate. Cases of encephalopathy have been observed in some patients, usual
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Malvern initiates European user group meetings for chemical imaging
7. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
8. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Inspire Announces Presentations at Two European Scientific Conferences
11. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Calif., Dec. 7, 2010 Anthera Pharmaceuticals, Inc. (Nasdaq: ... to treat serious diseases associated with inflammation, today announced ... 2010 European Society Pediatric Research Award at the Third ... in Copenhagen, Denmark where Dr. Daniele De Luca, MD, ...
... 2010 Alder Biopharmaceuticals Inc. today announced that data ... antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal ... cancer (NSCLC). After 12 weeks of treatment ... received ALD518 experienced hemoglobin level increases from less than ...
Cached Medicine Technology:Varespladib Receives 2010 European Society Pediatric Research Award 2Varespladib Receives 2010 European Society Pediatric Research Award 3Data from Phase 2 Study of Alder Biopharmaceuticals' Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer 2
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
(Date:7/9/2014)... Wakulich was told she had an aneurysm, she figured an ... , "I was devastated," said Wakulich, who is 56 years ... was a serious diagnosis. Then I met Dr. Bernard Bendok ... less invasive procedure. It was something I didn,t even know ... multi-center U.S. clinical trial to evaluate the safety and effectiveness ...
(Date:7/9/2014)... of stromal support cells and immune cells and ... in the development of diseases could open new ... was the conclusion of a review article by scientists ... Nature . , Prof. Peter Carmeliet: "Consider the ... of cancer cells has been examined in minute detail ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2
... researchers have found that even before infants begin to speak, ... infants, words influence performance in a cognitive task in a ... sounds, including musical tones. The research by ... department in the Weinberg College of Arts and Sciences, will ...
... ... three drive autoloader with a compact body suitable for any office space. , ... (Vocus) March 25, 2010 -- Vinpower Digital announced today the ... autoloader duplication system. This unit offers many of the options and benefits expected ...
... ... purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a ... ... Institute Inc. (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited ...
... ... technology can transform the way utilities can deliver power to customers," said President & ... ... have discovered that smart grid will change every aspect of their business -- from ...
... UCSF researchers have shown that delivering HIV prevention services to ... their sexual risk behaviors. The findings are available now ... Behavior " and are scheduled for publication in an upcoming ... reductions in sexual risk took place when the prevention interventions ...
... in normal-weight women, suggesting it protects against obesity , WEDNESDAY, ... a well-known marker of inflammation may help determine how much ... was not present in obese individuals, according to the research, ... March 25 issue of the New England Journal of ...
Cached Medicine News:Health News:Talk to your babies 2Health News:Vinpower Digital Introduces the 3 Drive CUBE Autoloader Series 2Health News:Aderans Research Acquires Intercytex Assets 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 3Health News:UCSF study finds clinic-based HIV prevention is effective in reducing risk behaviors 2Health News:Inflammation Molecule May Determine Fat Levels 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: